Skip to main content

NuProbe VarTrace Sanger Assays

NuProbe Global has launched VarTrace Sanger assays for ultrasensitive detection and quantification of cancer mutations with variant allele frequencies down to 0.1 percent. The company specifically launched three assays covering EGFR mutations for non-small-cell lung cancer; BRAF mutations for melanoma and thyroid cancer; and FLT3, DNMT3A, IDH1, IDH2, KIT, NPM1 mutations for acute myeloid leukemia. The assays are based on the firm's proprietary blocker displacement amplification (BDA) technology, and are compatible with both cell-free DNA from blood plasma and tissue samples including formalin-fixed paraffin-embedded tissue, NuProbe said.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.